The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Official Title: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001
Study ID: NCT00775073
Brief Summary: This is a prospective open label clinical trial in patients with advanced or metastatic liver cancer to assess the clinical and biological activity of RAD001 (Everolimus) in conjunction with Bevazicumab (Avastin). Approximately 36 patients will be enrolled.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Medizinische Klinik 1 University of Erlangen, Erlangen, Bavaria, Germany
Zollernalbklinikum, Balingen, , Germany
Charité, Campus Virchow Klinikum, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Berlin, , Germany
Universitaetsklinikum Bonn, Medizinische Klinik und Poliklinik I, Bonn, , Germany
Klinikum der J.-W.-Goethe-Universitaet, Medizinische Klinik I, Frankfurt, , Germany
Medizinische Universitaetsklinik Freiburg, Innere Medizin II, Freiburg, , Germany
Martin-Luther-Universitaet Halle-Wittenberg, Universitaetsklinik und Poliklinik für Innere Medizin I, Halle, , Germany
Medizinische Hochschule Hannover, Zentrum Innere Medizin, Hannover, , Germany
Universitätsklinikum des Saarlandes Klinik für Innere medizin II, Homburg/Saar, , Germany
Medizinische Fakultaet der Otto-von-Guericke-Universitaet, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Magdeburg, , Germany
Name: Gerhard Treiber, PD Dr.
Affiliation: Zollernalbklinikum Balingen
Role: PRINCIPAL_INVESTIGATOR